Introduction：Basic information about CAS 914453-97-7|Felypressin acetate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Felypressin acetate |
|---|
| CAS Number | 914453-97-7 | Molecular Weight | 1100.271 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C46H65N13O11S2.xC2H4O2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 1-{[(4R,7S,10S,13S,16S,19R)-19-Amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-lysylglycinamide acetate (1:1) |
|---|
| Synonym | More Synonyms |
|---|
Felypressin acetate BiologicalActivity
| Description | Felypressin acetate (PLV-2 acetate) is a non-catecholamine vasoconstrictor and a vasopressin 1 agonist. Felypressin acetate is widely used in dental procedures[1][2]. |
|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>GPCR/G Protein >>Vasopressin Receptor |
|---|
| Target | Vasopressin 1[2] |
|---|
| In Vitro | Felypressin is a synthetic hormone of the posterior pituitary lobe characterized by vasoconstrictor properties that is widely used in dental procedures. The vasoconstrictor action of Felypressin seems to be mediated by V1 receptors of the blood vessel smooth muscle cells[1]. |
|---|
| In Vivo | Felypressin can reduce toxicity during dental procedures. Felypressin increases the diastolic blood pressure of hypertensive patients with controlled blood pressure[1]. Cardiovascular effects of Felypressin (240 ng/kg; intravenous injection) are studied in Wistar rats. Felypressin induces a pressor effect. Felypressin depends on V1 receptors to induce pressor and bradycardic effects, and that it produces a high relationship between bradycardia and mean arterial pressure variation depending on area postrema and central V1 receptors[2]. |
|---|
| References | [1]. Bronzo AL et al. Felypressin increases blood pressure during dental procedures in hypertensive patients. Arq Bras Cardiol. 2012 Aug;99(2):724-31. [2]. Cecanho R et al. Cardiovascular effects of felypressin. Anesth Prog. 2006 Winter;53(4):119-25. |
|---|
Chemical & Physical Properties
| Molecular Formula | C46H65N13O11S2.xC2H4O2 |
|---|
| Molecular Weight | 1100.271 |
|---|
| Exact Mass | 1099.457886 |
|---|
| InChIKey | ZONQCMCHGLZABI-UHFFFAOYSA-N |
|---|
| SMILES | CC(=O)O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
|---|
| Storage condition | -20°C |
|---|
Synonyms
| 1-{[(4R,7S,10S,13S,16S,19R)-19-Amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-lysylglycinamide acetate (1:1) |
| Glycinamide, 1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-6,9,12,15,18-pentaoxo-13,16-bis(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]-L-prolyl-L-lysyl-, acetate (1:1) |
| Felypressin Acetate |
